DANAHER CORPORATION (DHR) FY2024 Q3 P&L / Income Statement

DANAHER CORPORATION (DHR) FY2024 Q3 P&L / Income Statement

Income statement for 2024-06-29 through 2024-09-27. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Sales

5,798,000,000 US dollars

Cost of sales

2,397,000,000 US dollars

Gross profit

3,401,000,000 US dollars

Operating expenses (calculated)

2,443,000,000 US dollars

Operating profit

958,000,000 US dollars

Other income (expense), net (calculated)

19,000,000 US dollars

Earnings before income taxes

977,000,000 US dollars

Income taxes

159,000,000 US dollars

Net earnings

818,000,000 US dollars

Biotechnology

1,653,000,000 US dollars

Life Sciences

1,782,000,000 US dollars

Diagnostics

2,363,000,000 US dollars

Research and development expenses

383,000,000 US dollars

Selling, general and administrative expenses

2,060,000,000 US dollars

Earnings from discontinued operations, net of income taxes

0 US dollars. Reported below-tax contribution to net income.

Biotechnology costs (calculated)

1,263,000,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.

Life Sciences costs (calculated)

1,747,000,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.

Diagnostics costs (calculated)

1,748,000,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.

Reconciling items (calculated)

82,000,000 US dollars. Segment revenue less segment operating income; it includes cost of revenue and operating expenses.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.